Literature DB >> 32844566

Activity of Riminophenazines against Mycobacterium tuberculosis: A Review of Studies that Might be Contenders for Use as Antituberculosis Agents.

Mpelegeng Victoria Bvumbi1.   

Abstract

Tuberculosis is one of the leading cause of death in the world, mainly due to the increasing number of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains. Factors such as the HIV pandemic contribute further. Also, the ineffectiveness of the chemotherapy in current use increases the mortality rate. Therefore, new and repurposed antituberculosis drugs are urgently needed for the treatment of MDR-TB, and riminophenazines are among those drugs that are being reinvestigated for their potential in the treatment of TB. This review delivers a brief historical account of riminophenazines, their general synthesis, mechanisms of action, and their physicochemical properties. The discussion is limited to those studies that investigated the activity of these compounds as antituberculosis agents. Given their unique properties, this review will be of great significance in giving direction towards the design and development of new riminophenazine analogues.
© 2020 The Authors. Published by Wiley-VCH GmbH.

Entities:  

Keywords:  MDR-TB; Mycobacterium tuberculosis; drug discovery; medicinal chemistry; riminophenazines

Mesh:

Substances:

Year:  2020        PMID: 32844566      PMCID: PMC7756396          DOI: 10.1002/cmdc.202000580

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.540


  42 in total

1.  In-vivo activity of streptomycin and clofazimine against established infections of Mycobacterium avium complex in beige mice.

Authors:  P R Gangadharam; K Parikh
Journal:  J Antimicrob Chemother       Date:  1992-12       Impact factor: 5.790

Review 2.  THE ANTIMYCOBACTERIAL ACTIVITY OF B 663.

Authors:  V C BARRY; M L CONALTY
Journal:  Lepr Rev       Date:  1965-01       Impact factor: 0.537

3.  Physicochemical properties of antibacterial compounds: implications for drug discovery.

Authors:  Rosemarie O'Shea; Heinz E Moser
Journal:  J Med Chem       Date:  2008-02-09       Impact factor: 7.446

4.  WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

Authors:  D Falzon; E Jaramillo; H J Schünemann; M Arentz; M Bauer; J Bayona; L Blanc; J A Caminero; C L Daley; C Duncombe; C Fitzpatrick; A Gebhard; H Getahun; M Henkens; T H Holtz; J Keravec; S Keshavjee; A J Khan; R Kulier; V Leimane; C Lienhardt; C Lu; A Mariandyshev; G B Migliori; F Mirzayev; C D Mitnick; P Nunn; G Nwagboniwe; O Oxlade; D Palmero; P Pavlinac; M I Quelapio; M C Raviglione; M L Rich; S Royce; S Rüsch-Gerdes; A Salakaia; R Sarin; D Sculier; F Varaine; M Vitoria; J L Walson; F Wares; K Weyer; R A White; M Zignol
Journal:  Eur Respir J       Date:  2011-08-04       Impact factor: 16.671

5.  Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection.

Authors:  R G Kansal; R Gomez-Flores; I Sinha; R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 6.  Clofazimine: current status and future prospects.

Authors:  Moloko C Cholo; Helen C Steel; P B Fourie; Willem A Germishuizen; Ronald Anderson
Journal:  J Antimicrob Chemother       Date:  2011-10-20       Impact factor: 5.790

7.  Activity of phenazine analogs against Mycobacterium leprae infections in mice.

Authors:  R M Van Landingham; L L Walker; J F O'Sullivan; T M Shinnick
Journal:  Int J Lepr Other Mycobact Dis       Date:  1993-09

8.  Management of drug-resistant TB in patients with HIV co-infection.

Authors:  Graeme Meintjes
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

9.  Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study.

Authors:  Ali Nasir Siddiqui; Khalid Umer Khayyam; Manju Sharma
Journal:  Biomed Res Int       Date:  2016-08-24       Impact factor: 3.411

10.  Risk factors for tuberculosis.

Authors:  Padmanesan Narasimhan; James Wood; Chandini Raina Macintyre; Dilip Mathai
Journal:  Pulm Med       Date:  2013-02-12
View more
  1 in total

Review 1.  Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.

Authors:  Klaudia T Angula; Lesetja J Legoabe; Richard M Beteck
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.